Use of localised gene transfer to develop new treatment strategies for the salivary component of Sjögren's syndrome

Annals of the Rheumatic Diseases

Volumn 62, Issue 11, 2003, Pages 1038-1046

  Kok, M R ^a,b   Baum, B J ^b   Tak, P P ^a   Pillemer, S R ^b  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CELL ADHESION MOLECULE; FODRIN; INTERLEUKIN 10; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MUSCARINIC M3 RECEPTOR;

AGE DISTRIBUTION; APOPTOSIS; B LYMPHOCYTE; CLINICAL FEATURE; CLINICAL PRACTICE; DNA VECTOR; DRUG SAFETY; GENE TARGETING; GENE TECHNOLOGY; GENE TRANSFER; HUMAN; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; KERATOCONJUNCTIVITIS SICCA; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE STRAIN; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SALIVARY GLAND; SCID MOUSE; SEX RATIO; SJOEGREN SYNDROME; SPECIES COMPARISON; STATISTICAL SIGNIFICANCE; STRAIN DIFFERENCE; T LYMPHOCYTE; TREATMENT INDICATION; VIRAL GENE DELIVERY SYSTEM; XEROSTOMIA;

ANIMALS; CYTOKINES; DEPENDOVIRUS; GENE THERAPY; GENETIC VECTORS; HUMANS; MICE; MICE, INBRED NOD; MICE, TRANSGENIC; RECEPTORS, TUMOR NECROSIS FACTOR; SJOGREN'S SYNDROME;

EID: 0142187613     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.62.11.1038     Document Type: Review

References (96)

1. Bloch BW, Wohl MJ, Bunim JJ. Sjögren's syndrome. A clinical, pathological and serological study of sixty-two cases. Medicine (Baltimore) 1965;44:187-231.
2. Adamson TCd, Fox RI, Frisman DM, Howell FV. Immunohistologic analysis of lymphoid infiltrates in primary Sjögren's syndrome using monoclonal antibodies. J Immunol 1983;130:203-8.
3. Pillemer SR, Matteson EL, Jacobsson LT, Martens PB, Melton LJ 3rd, O'Fallon WM, et al. Incidence of physician-diagnosed primary Sjögren syndrome in residents of Olmsted County, Minnesota. Mayo Clin Proc 2001;76:593-9.
4. Fox PC, Brennan M, Di Sun P. Cytokine expression in human labial minor salivary gland epithelial cells in health and disease. Arch Oral Biol 1999;44(suppl 1):S49-52.
5. Fox PC, van der Ven PF, Baum BJ, Mandel ID. Pilocarpine for the treatment of xerostomia associated with salivary gland dysfunction. Oral Surg Oral Med Oral Pathol 1986;61:243-8.
6. Kruize AA, Hene RJ, Kallenberg CG, van Bijsterveld OP, van der Heide A, Kater L, et al. Hydroxychloroquine treatment for primary Sjögren's syndrome: a two year double blind crossover trial. Ann Rheum Dis 1993;52:360-4.
7. Fox PC, Datiles M, Atkinson JC, Macynski AA, Scott J, Fletcher D, et al. Prednisone and piroxicam for treatment of primary Sjögren's syndrome. Clin Exp Rheumatol 1993;11:149-56.
8. Evans CH, Ghivizzani SC, Kang R, Muzzonigro T, Wasko MC, Herndon JH, et al. Gene therapy for rheumatic diseases. Arthritis Rheum 1999;42:1-16.
9. Baum BJ, O'Connell BC. In vivo gene transfer to salivary glands. Crit Rev Oral Biol Med 1999;10:276-83.
10. Vervoordeldonk MJ, Tak PP. Gene therapy in rheumatic diseases. Best Pract Res Clin Rheumatol 2001;15:771-88.
11. Kay MA, Glorioso JC, Naldini L. Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. Nat Med 2001;7:33-40.
12. Fox RI, Michelson P, Casiano CA, Hayashi J, Stern M. Sjögren's syndrome. Clin Dermatol 2000;18:589-600.
13. Jonsson R, Haga H-J, Gordon TP. Sjögren's syndrome. In: Koopman WJ, ed. Arthritis and allied conditions: a textbook of rheumatology, 14th ed. Philadelphia: Lippincott Williams & Wilkins, 2001:1736-59.
14. Zheng C, Hoque AT, Braddon VR, Baum BJ, O'Connell BC. Evaluation of salivary gland acinar and ductal cell-specific promoters in vivo with recombinant adenoviral vectors. Hum Gene Ther 2001;12:2215-23.
15. Kagami H, Atkinson JC, Michalek SM, Handelman B, Yu S, Baum BJ, et al. Repetitive adenovirus administration to the parotid gland: role of immunological barriers and induction of oral tolerance. Hum Gene Ther 1998;9:305-13.
16. Nishikawa M, Huang L. Nonviral vectors in the new millennium: delivery barriers in gene transfer. Hum Gene Ther 2001;12:861-70.
17. Shai E, Falk H, Honigman A, Panet A, Palmon A. Gene transfer mediated by different viral vectors following direct cannulation of mouse submandibular salivary glands. Eur J Oral Sci 2002;110:254-60.
18. Morgan RA, Anderson WF. Human gene therapy. Annu Rev Biochem 1993;62:191-217.
19. Schnell MA, Zhang Y, Tazelaar J, Gao GP, Yu QC, Qian R, et al. Activation of innate immunity in nonhuman primates following intraportal administration of adenoviral vectors. Mol Ther 2001;3(5 Pt 1):708-22.
20. Zhao N, Liu DP, Liang CC. Hot topics in adeno-associated virus as a gene transfer vector. Mol Biotechnol 2001;19:229-37.
21. Yamano S, Huang LY, Ding C, Chiorini JA, Goldsmith CM, Wellner RB, et al. Recombinant adeno-associated virus serotype 2 vectors mediate stable interleukin 10 secretion from salivary glands into the bloodstream. Hum Gene Ther 2002;13:287-98.
22. Braddon VR, Chiorini JA, Wang S, Kotin RM, Baum BJ. Adenoassociated virus-mediated transfer of a functional water channel into salivary epithelial cells in vitro and in vivo. Hum Gene Ther 1998;9:2777-85.
23. Hoque AT, Baccaglini L, Baum BJ. Hydroxychloroquine enhances the endocrine secretion of adenovirus-directed growth hormone from rat submandibular glands in vivo. Hum Gene Ther 2001;12:1333-41.
24. Baum BJ, Wellner R, Zheng C. Gene transfer to salivary glands. Int Rev Cytol 2001;213:93-146.
25. Mastrangeli A, O'Connell B, Aladib W, Fox PC, Baum BJ, Crystal RG. Direct in vivo adenovirus-mediated gene transfer to salivary glands. Am J Physiol 1994;266(6 Pt 1):G1146-55.
26. Marshall E. Gene therapy: viral vectors still pack surprises. Science 2001;294:1640.
27. Leiden JM. Gene therapy - promise, pitfalls, and prognosis. N Engl J Med 1995;333:871-3.
28. Hacein-Bey-Abina S, von Kalle C, Schmidt M, Le Deist F, Wulffraat N, McIntyre E, et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2003;348:255-6.
29. Ioannidis JP, Vassiliou VA, Moutsopoulos HM. Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjögren's syndrome. Arthritis Rheum 2002;46:741-7.
30. Strombeck B, Ekdahl C, Manthorpe R, Wikstrom I, Jacobsson L. Health-related quality of life in primary Sjögren's syndrome, rheumatoid arthritis and fibromyalgia compared to normal population data using SF-36. Scand J Rheumatol 2000;29:20-8.
31. Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986;136:2348-57.
32. Abbas AK, Murphy KM, Sher A. Functional diversity of helper T lymphocytes. Nature 1996;383:787-93.
33. Salgame P, Abrams JS, Clayberger C, Goldstein H, Convit J, Modlin RL, et al. Differing lymphokine profiles of functional subsets of human CD4 and CD8 T cell clones. Science 1991;254:279-82.
34. Mosmann TR, Coffman RL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989,7:145-73.
35. Umetsu DT, Jabara HH, DeKruyff RH, Abbas AK, Abrams JS, Geha RS. Functional heterogeneity among human inducer T cell clones. J Immunol 1988;140:4211-16.
36. Zumla A, Mathur M, Stewart J, Wilkinson L, Isenberg D. T cell receptor expression in Sjögren's syndrome. Ann Rheum Dis 1991;50:691-3.
37. Ferraccioli GF, De Vita S. Cytokine expression in the salivary glands of Sjögren's syndrome patients in relation to tissue infiltration and lymphoepithelial lesions. Arthritis Rheum 1997;40:987-90.
38. Fox RI, Kang HI, Ando D, Abrams J, Pisa E. Cytokine mRNA expression in salivary gland biopsies of Sjögren's syndrome. J Immunol 1994;152:5532-9.
39. Fox PC, Grisius MM, Bermudez DK, Sun D. Cytokine mRNA expression in labial salivary glands and cytokine secretion in parotid saliva in Sjögren's syndrome. Adv Exp Med Biol 1998;438:909-15.
40. Ohyama Y, Nakamura S, Matsuzaki G, Shinohara M, Hiroki A, Fujimura T, et al. Cytokine messenger RNA expression in the labial salivary glands of patients with Sjögren's syndrome. Arthritis Rheum 1996;39:1376-84.
41. Moutsopoulos HM. Sjögren's syndrome: autoimmune epithelitis. Clin Immunol Immunopathol 1994;72:162-5.
42. Sun D, Emmert-Buck MR, Fox PC. Differential cytokine mRNA expression in human labial minor salivary glands in primary Sjögren's syndrome. Autoimmunity 1998;28:125-37.
43. Mitsias DI, Tzioufas AG, Veiopoulou C, Zintzaras E, Tassios IK, Kogopoulou O, et al. The Th1/Th2 cytokine balance changes with the progress of the immunopathological lesion of Sjögren's syndrome. Clin Exp Ilmmunol 2002;128:562-8.
44. Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000;343:1586-93.
45. Steinfeld SD, Demols P, Salmon I, Kiss R, Appelboom T. Infliximab in patients with primary Sjögren's syndrome: a pilot study. Arthritis Rheum 2001;44:2371-5.
46. Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001;19:683-765.
47. van Roon JA, van Roy JL, Gmelig-Meyling FH, Lafeber FP, Bijlsma JW. Prevention and reversal of cartilage degradation in rheumatoid arthritis by interleukin-10 and interleukin-4. Arthritis Rheum 1996;39:829-35.
48. Yamano S, Kok M, Tsutsui M, Tak P, Pillemer S, Baum B. Local IL-10 gene transfer with an adeno-associated virus in a murine model of Sjögren's syndrome enhances salivary flow. Molecular Therapy 2002;5(suppl):s4-5.
49. Yamano S, Scott DE, Huang LY, Mikolajczyk M, Pillemer SR, Chiorini JA, et al. Protection from experimental endotoxemia by a recombinant adeno-associated virus encoding interleukin 10. J Gene Med 2001;3:450-7.
50. Cortes J, Kurzrock R. Interleukin-10 in non-Hodgkin's lymphoma. Leuk Lymphoma 1997;26:251-9.
51. Go NF, Castle BE, Barrett R, Kastelein R, Dang W, Mosmann TR, et al. Interleukin 10, a novel B cell stimulatory factor: unresponsiveness of X chromosome-linked immunodeficiency B cells. J Exp Med 1990;172:1625-31.
52. Shin SS, Sheibani K, Fishleder A, Ben-Ezra J, Bailey A, Koo CH, et al. Monocytoid B-cell lymphoma in patients with Sjögren's syndrome: a clinicopathologic study of 13 patients. Hum Pathol 1991;22:422-30.
53. Sfikakis PP, Mavrikakis M. Adhesion and lymphocyte costimulatory molecules in systemic rheumatic diseases. Clin Rheumatol 1999;18:317-27.
54. Saito I, Terauchi K, Shimuta M, Nishiimura S, Yoshino K, Takeuchi T, et al. Expression of cell adhesion molecules in the salivary and lacrimal glands of Sjögren's syndrome. J Clin Lab Anal 1993,7:180-7.
55. Westermann J, Engelhardt B, Hoffmann JC. Migration of T cells in vivo: molecular mechanisms and clinical implications. Ann Intern Med 2001;135:279-95.
56. Skopouli FN, Fox PC, Galanopoulou V, Atkinson JC, Jaffe ES, Moutsopoulos HM. T cell subpopulations in the labial minor salivary gland histopathologic lesion of Sjögren's syndrome. J Rheumatol 1991;18:210-14.
57. Kong L, Ogawa N, McGuff HS, Nakabayashi T, Sakata KM, Masago R, et al. Bcl-2 family expression in salivary glands from patients with primary Sjögren's syndrome: involvement of Bax in salivary gland destruction. Clin Immunol Immunopathol 1998;88:133-41.
58. Ogawa N, Dang H, Kong L, Anaya JM, Liu GT, Talal N. Lymphocyte apoptosis and apoptosis-associated gene expression in Sjögren's syndrome. Arthritis Rheum 1996;39:1875-85.
59. Oxholm P, Daniels TE, Bendtzen K. Cytokine expression in labial salivary glands from patients with primary Sjögren's syndrome. Autoimmunity 1992;12:185-91.
60. Linsley PS, Wallace PM, Johnson J, Gibson MG, Greene JL, Ledbetter JA, et al. Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule. Science 1992;257:792-5.
61. Datta SK, Kalled SL. CD40-CD40 ligand interaction in autoimmune disease. Arthritis Rheum 1997;40:1735-45.
62. Mariette X, Roux S, Zhang J, Bengoufa D, Lavie F, Zhou T, et al. The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjögren's syndrome. Ann Rheum Dis 2003;62:168-71.
63. Groom J, Kalled SL, Cutler AH, Olson C, Woodcock SA, Schneider P, et al. Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjögren's syndrome. J Clin Invest 2002;109:59-68.
64. Edwards JC, Cambridge G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology (Oxford) 2001;40:205-11.
65. Bacman S, Sterin-Borda L, Camusso JJ, Arana R, Hubscher O, Borda E. Circulating antibodies against rat parotid gland M3 muscarinic receptors in primary Sjögren's syndrome. Clin Exp Immunol 1996;104:454-9.
66. Bacman S, Perez Leiros C, Sterin-Borda L, Hubscher O, Arana R, Borda E. Autoantibodies against lacrimal gland M3 muscarinic acetylcholine receptors in patients with primary Sjögren's syndrome. Invest Ophthalmol Vis Sci 1998;39:151-6.
67. Fox RI, Konttinen Y, Fisher A. Use of muscarinic agonists in the treatment of Sjögren's syndrome. Clin Immunol 2001;101:249-63.
68. Waterman SA, Gordon TP, Rischmueller M. Inhibitory effects of muscarinic receptor autoantibodies on parasympathetic neurotransmission in Sjögren's syndrome. Arthritis Rheum 2000;43:1647-54.
69. Itoh N, Yonehara S, Ishii A, Yonehara M, Mizushima S, Sameshima M, et al. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 1991;66:233-43.
70. Patel YI, McHugh NJ. Apoptosis-new clues to the pothogenesis of Sjögren's syndrome? Rheumatology (Oxford) 2000;39:119-21.
71. Nagaraju K, Cox A, Casciola-Rosen L, Rosen A. Novel fragments of the Sjögren's syndrome autoantigens alpha-fodrin and type 3 muscarinic acetylcholine receptor generated during cytotoxic lymphocyte granule-induced cell death. Arthritis Rheum 2001;44:2376-86.
72. Ohlsson M, Skarstein K, Bolstad AI, Johannessen AC, Jonsson R. Fas-induced apoptosis is a rare event in Sjögren's syndrome. Lab Invest 2001;81:95-105.
73. Kong L, Ogawa N, Nakabayashi T, Liu GT, D'Souza E, McGuff HS, et al. Fas and Fas ligand expression in the salivary glands of patients with primary Sjögren's syndrome. Arthritis Rheum 1997;40:87-97.
74. Mariette X, Sibilia J, Roux S, Meignin V, Janin A. A new defensive mechanism to prevent apoptosis in salivary ductal cells from patients with Sjögren's syndrome: over-expression of p53 and p21. Rheumatology (Oxford) 2002;41:96-9.
75. Humphreys-Beher MG, Brayer J, Yamachika S, Peck AB, Jonsson R. An alternative perspective to the immune response in autoimmune exocrinopathy: induction of functional quiescence rather than destructive autoaggression. Scand J Immunol 1999;49:7-10.
76. Pedersen AM, Dissing S, Fahrenkrug J, Hannibal J, Reibel J, Nauntofte B. Innervation pattern and Ca2+ signalling in labial salivary glands of healthy individuals and patients with primary Sjögren's syndrome (pSS). J Oral Pathol Med 2000;29:97-109.
77. Kessler HS. A laboratory model for Sjögren's syndrome. Am J Pathol 1968;52:671-85.
78. Wolff A, Scott J, Woods K, Fox PC. An investigation of parotid gland function and histopathology in autoimmune disease-prone mice of different age groups. J Oral Pathol Med 1991;20:486-9.
79. Jonsson R, Tarkowski A, Backman K, Holmdahl R, Klareskog L. Sialadenitis in the MRL-I mouse: morphological and immunohistochemical characterization of resident and infiltrating cells. Immunology 1987;60:611-16.
80. Hayashi Y, Haneji N, Hamano H, Yanagi K, Takahashi M, Ishimaru N. Effector mechanism of experimental autoimmune sialadenitis in the mouse model for primary Sjögren's syndrome. Cell Immunol 1996;171:217-25.
81. Hayashi Y, Haneji N, Hamano H. Pathogenesis of Sjögren's syndrome-like autoimmune lesions in MRL/lpr mice. Pathol Int 1994;44:559-68.
82. Hamano H, Saito I, Haneji N, Mitsuhashi Y, Miyasaka N, Hayashi Y. Expressions of Cytokine genes during development of autoimmune sialadenitis in MRL/lpr mice. Eur J Immunol 1993;23:2387-91.
83. Furukawa F. Animal models of cutaneous lupus erythematosus and lupus erythematosus photosensitivity. Lupus 1997;6:193-202.
84. Koopman WJ, Gay S. The MRL-lpr/lpr mouse. A model for the study of rheumatoid arthritis. Scand J Rheumatol Suppl 1988;75:284-9.
85. Le Hir M, Martin M, Haas C. A syndrome resembling human systemic sclerosis (scleroderma) in MRL/lpr mice lacking interferon-gamma (IFN-gamma) receptor (MRL/lprgammaR-/-). Clin Exp Immunol 1999;115:281-7.
86. Haneji N, Hamano H, Yanagi K, Hayashi Y. A new animal model for primary Sjögren's syndrome in NFS/sld mutant mice. J Immunol 1994;153: 2769-77.
87. Haneji N, Nakamura T, Tokio K, Yanagi K, Higashiyama H, Saito I, et al. Identification of alpha-fodrin as a candidate autoantigen in primary Sjögren's syndrome. Science 1997;276:604-7.
88. Witte T, Matthias T, Arnett FC, Peter HH, Hartung K, Sachse C, et al. IgA and IgG autoantibodies against alpha-fodrin as markers for Sjögren's syndrome. Systemic lupus erythematosus. J Rheumatol 2000;27:2617-20.
89. Humphreys-Beher MG, Hu Y, Nakagawa Y, Wang PL, Purushotham KR. Utilization of the non-obese diabetic (NOD) mouse as an animal model for the study of secondary Sjögren's syndrome. Adv Exp Med Biol 1994;350:631-6.
90. Makino S, Kunimoto K, Muraoka Y, Mizushima Y, Katagiri K, Tochino Y. Breeding of a non-obese, diabetic strain of mice. Jikken Dobutsu 1980;29:1-13.
91. Yamano S, Atkinson JC, Baum BJ, Fox PC. Salivary gland cytokine expression in NOD and normal BALB/c mice. Clin Immunol 1999;92:265-75.
92. Lund T, O'Reilly L, Hutchings P, Kanagawa O, Simpson E, Gravely R, et al. Prevention of insulin-dependent diabetes mellitus in non-obese diabetic mice by transgenes encoding modified I-A beta-chain or normal I-E alpha-chain. Nature 1990;345:727-9.
93. Robinson CP, Yamachika S, Bounous DI, Braver J, Jonsson R, Holmdahl R, et al. A novel NOD-derived murine model of primary Sjögren's syndrome. Arthritis Rheum 1998;41:150-6.
94. Robinson CP, Yamamoto H, Peck AB, Humphreys-Beher MG. Genetically programmed development of salivary gland abnormalities in the NOD (nonobese diabetic)-scid mouse in the absence of detectable lymphocytic infiltration: a potential trigger for sialoadenitis of NOD mice. Clin Immunol Immunopathol 1996;79:50-9.
95. Van Blokland SC, Van Helden-Meeuwsen CG, Wierenga-Wolf AF, Tielemans D, Drexhage HA, Van De Merwe JP, et al. Apoptosis and apoptosis-related molecules in the submandibular gland of the nonobese diabetic mouse model for Sjögren's syndrome: limited role for apoptosis in the development of sialoadenitis. Lab Invest 2003;83:3-11.
96. Martens PB, Pillemer SR, Jacobsson LT, O'Fallon WM, Matteson EL. Survivorship in a population based cohort of patients with Sjögren's syndrome, 1976-1992. J Rheumatol 1999;26:1296-300.